Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cervical carcinoma is the fourth most common cause of death in woman, caused by human papillomavirus (HPV) infections and arising from the cervix.
Cytoskeleton-associated protein 2
(
CKAP2
), also known as tumor-associated microtubule-associated protein, has been linked to tumorigenic effects. In the present study, we screened
CKAP2
as a new candidate gene which promotes development of cervical carcinoma, in two independent datasets (TCGA and GSE27678). Results showed that
CKAP2
expression was significantly up-regulated in cervical cancerous tissues compared with normal counterparts. Gene set enrichment analysis (GSEA) showed that metastasis, cell cycle and
FAK
pathways were related with elevated
CKAP2
expression. Knockdown of
CKAP2
expression significantly inhibited cell proliferation, migration and invasion both in HeLa and C-33A cells. And depletion of
CKAP2
down-regulated the expression of metastasis and cell cycle related proteins as well as the phosphorylation of ERK2 (p-ERK2), except E-cadherin. In vivo experiment revealed that knockdown of
CKAP2
inhibited C-33A cells proliferation. However,
FAK
inhibitor PF-562271 and ERK2 inhibitor VX-11e treatment significantly inhibited
CKAP2
overexpression-induced cell proliferation, migration and invasion in SiHa cells. In conclusion, our study suggests that
CKAP2
acts as a functional oncogene in cervical carcinoma development and may exert its function by targeting
FAK
-ERK2 signaling pathway.
...
PMID:Involvement of FAK-ERK2 signaling pathway in CKAP2-induced proliferation and motility in cervical carcinoma cell lines. 2852 60
Osteosarcoma is the most common primary bone malignancy, mainly occurring in children and adolescents.
Cytoskeleton-associated protein 2
(
CKAP2
), which plays important roles in cell proliferation, has been reported to be overexpressed in diverse human cancers. In the present study, we aimed at exploring the expression and functions of
CKAP2
in osteosarcoma. The mRNA and protein expression of
CKAP2
was analyzed on collected osteosarcoma and control bone cyst tissues. The results indicated that
CKAP2
expression was remarkably elevated in osteosarcoma tissues compared with bone cysts tissues. The expression level of
CKAP2
in osteosarcoma was associated with overall survival, tumor size and tumor stage. In addition, down-regulation of
CKAP2
by RNA interference in osteosarcoma cell lines, MG63 and SW1353, caused a remarkable inhibition in cell proliferation in vitro and xenograft growth in nude mice. Silencing of
CKAP2
also significantly induced G0/G1 arrest and cell apoptosis of osteosarcoma cells. Furthermore, phosphorylation levels of
Janus kinase 2
(
JAK2
) and Signal transducers and activators of transcription 3 (STAT3) were significantly reduced in
CKAP2
knockdown cells. The expression of downstream targets of
JAK2
/STAT3 signaling, Cyclin D1, Bcl-2 and survivin, was also decreased in
CKAP2
knockdown cells. Such aberrations can be rescued by re-expression of RNAi-resistant
CKAP2
. Collectively, the present study indicates that
CKAP2
is a potential oncogene by targeting
JAK2
/STAT3 signaling, and that
CKAP2
may serve as a novel target for osteosarcoma therapy.
...
PMID:Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells. 3011 12